Search Results
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia submissão regulatória suplementar de MINJUVI® (tafasitamabe) para linfoma folicular na Argentina e no México
A Knight firmou, em 2021, um acordo exclusivo de fornecimento e distribuição com a Incyte (NASDAQ: INCY) para tafasitamabe (comercializado como MONJUVI® [tafasitamab-cxix] nos Estados Unidos e MINJUVI® fora dos EUA) em toda a América Latina. A Knight lançou
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la presentación regulatoria complementaria de MINJUVI® (tafasitamab) para linfoma folicular en Argentina y México
Knight firmó en 2021 un acuerdo exclusivo de suministro y distribución con Incyte (NASDAQ: INCY) para tafasitamab (comercializado como MONJUVI® [tafasitamab–cxix] en Estados Unidos y MINJUVI® fuera de EE. UU.) en toda América Latina. Knight ha lanzado
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics Anuncia Aprovação de Indicação Adicional para MINJUVI® (tafasitamabe) no Brasil
benefício da empresa e de nossos parceiros."A Knight firmou, em 2021, um acordo exclusivo de fornecimento e distribuição com a Incyte (NASDAQ: INCY) para tafasitamabe (comercializado como MONJUVI® [tafasitamab-cxix] nos Estados Unidos e MINJUVI® fora dos EUA) em toda a América Latina. A Knight lançou
More news about: Knight Therapeutics Inc.
Mar 17, 2026, 07:35 ET Knight Therapeutics anuncia la aprobación de una indicación adicional para MINJUVI® (tafasitamab) en Brasil
enfocada en beneficio de Knight y nuestros socios." Knight firmó en 2021 un acuerdo exclusivo de suministro y distribución con Incyte (NASDAQ: INCY) para tafasitamab (comercializado como MONJUVI® [tafasitamab–cxix] en Estados Unidos y MINJUVI® fuera de EE. UU.) en toda América Latina. Knight ha lanzado
More news about: Knight Therapeutics Inc.
Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
RLAY), Elevar Therapeutics, Eli Lilly (NYSE: LLY), Cogent Biosciences (Cogent Biosciences),Tanabe Pharma America (TYO: 4508), Incyte (NASDAQ: INCY), Roche (SWX: ROG), Genentech, LoxoOncology (NASDAQ: LOXO), Jazz Pharmaceuticals (NASDAQ: JAZZ), Daiichi Sankyo (TYO: 4568), and others
More news about: DelveInsight Business Research, LLP
Feb 27, 2026, 08:11 ET Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
INDIANAPOLIS, Feb. 27, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant
More news about: Eli Lilly and Company
Feb 19, 2026, 17:31 ET Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
(NASDAQ: HCWB), ALYS Pharmaceuticals, Dren Bio, Nektar Therapeutics (NASDAQ: NKTR), Eli Lilly and Company (NYSE: LLY), Incyte Corporation (NASDAQ: INCY), Pfizer (NYSE: PFE), Sun Pharmaceuticals (NSE: SUNPHARMA), and others
More news about: DelveInsight Business Research, LLP
Feb 16, 2026, 17:31 ET Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
Chugai Pharmaceutical (TYO: 4519), Galderma, Maruho, AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), Regeneron Pharmaceuticals (NASDAQ: REGN), Incyte (NASDAQ: INCY), Japan Tobacco (TYO: 2914), Otsuka Pharmaceutical, Medimetriks Pharmaceuticals, Acrotech Biopharma, and others
More news about: DelveInsight Business Research, LLP
Oct 24, 2025, 06:45 ET Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
INDIANAPOLIS, Oct. 24, 2025 /PRNewswire/ -- New results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) showed once-daily, oral baricitinib 4 mg helped the majority of adolescent patients (ages 12 to <18) with severe alopecia areata (AA) achieve successful
More news about: Eli Lilly and Company
Sep 15, 2025, 16:25 ET Alger Russell Innovation Index Updates for Third Quarter 2025
Incyte Corp. INCY Addition
More news about: Alger